Colloids and Surfaces B Biointerfaces, Journal Year: 2025, Volume and Issue: unknown, P. 114860 - 114860
Published: June 1, 2025
Language: Английский
EBioMedicine, Journal Year: 2024, Volume and Issue: 107, P. 105301 - 105301
Published: Aug. 23, 2024
Increasing evidence indicates that immunotherapy is hindered by a hostile tumor microenvironment (TME) featured with deprivation of critical nutrients and pooling immunosuppressive metabolites. Tumor cells outcompete immune effector for essential nutrients. Meanwhile, wide range cell-derived toxic metabolites exerts negative impacts on anti-tumor response, diminishing the efficacy immunotherapy. Nanomedicine excellent targetability offers novel approach to improving cancer via metabolically reprogramming TME. Herein, we review recent strategies enhancing immunotherapeutic effects through rewiring metabolism nanomedicine. Attention drawn immunometabolic tactics stromal in TME Additionally, discuss future directions developing metabolism-regulating nanomedicine precise efficacious
Language: Английский
Citations
86
Theranostics, Journal Year: 2024, Volume and Issue: 15(3), P. 993 - 1016
Published: Dec. 2, 2024
Immunotherapy has transformed current cancer management, and it achieved significant progress over last decades. However, an immunosuppressive tumor microenvironment (TME) diminishes the effectiveness of immunotherapy by suppressing activity immune cells facilitating immune-evasion. Adenosine monophosphate-activated protein kinase (AMPK), a key modulator cellular energy metabolism homeostasis, gained growing attention in anti-tumor immunity. Metformin is usually considered as cornerstone diabetes its role activating AMPK pathway also been extensively explored therapy although findings on remain inconsistent. nanomedicine formulation found to hold potential reprogramming TME through immunometabolic modulation both cells. This review elaborates foundation via metformin-based nanomedicines, offering valuable insights for next generation therapy.
Language: Английский
Citations
44
Theranostics, Journal Year: 2025, Volume and Issue: 15(5), P. 1689 - 1714
Published: Jan. 2, 2025
In recent years, nano-drug delivery systems (Nano-DDS) that target the tumor microenvironment (TME) to overcome multidrug resistance (MDR) have become a research hotspot in field of cancer therapy. By precisely targeting TME and regulating its unique pathological features, such as hypoxia, weakly acidic pH, abnormally expressed proteins, etc., these Nano-DDS enable effective therapeutic agents reversal MDR. This scientific community is increasing investment development diversified exploring their anti-drug potential. Therefore, it particularly important conduct comprehensive review progress TME-targeted years. After brief introduction MDR, design principle structure liposomes, polymer micelles inorganic nanocarriers are focused on, characteristics described. It also demonstrates how break through MDR treatment various mechanisms, discusses synthetic innovation, results overcoming mechanisms. The was concluded with deliberations on key challenges future outlooks
Language: Английский
Citations
5
Journal of Nanobiotechnology, Journal Year: 2025, Volume and Issue: 23(1)
Published: March 4, 2025
The tumor microenvironment (TME) is a complex and dynamic ecosystem that plays critical role in cancer progression. It comprises various cell types, including immune cells, stromal cells. Among these, cancer-associated fibroblasts (CAFs) represent heterogeneous population with diverse origins, phenotypes, functions. Activated CAFs secrete multiple factors promote growth, migration, angiogenesis, contribute to chemoresistance. Additionally, extracellular matrix (ECM) components, such as collagen, which form physical barrier hinders the penetration of chemotherapeutic immunotherapeutic agents. This ECM also influences infiltration, impeding their ability effectively target As result, modulating activity has emerged promising strategy enhance efficacy immunotherapy. Nano-delivery systems, constructed from nanomaterials high targeting specificity biocompatibility, offer compelling approach deliver therapeutic agents or immunomodulatory directly CAFs. modulation can alter CAF function, reduce tumor-promoting effects, thereby improve outcomes review provides an in-depth exploration functions, interactions within TME, particularly context suppression. Furthermore, it discusses potential applications functional nanocarrifers enhancing effectiveness immunotherapy, highlighting significant progress nanotechnology this area.
Language: Английский
Citations
3
International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(13), P. 7226 - 7226
Published: June 30, 2024
Breast cancer represents the most prevalent form of and leading cause cancer-related mortality among females worldwide. It has been reported that several risk factors contribute to appearance progression this disease. Despite advancements in breast treatment, a significant portion patients with distant metastases still experiences no cure. The extracellular matrix potential target for enhanced serum biomarkers cancer. Furthermore, degradation epithelial–mesenchymal transition constitute primary stages local invasion during tumorigenesis. Additionally, microbiome influence on diverse physiological processes. is emerging microbial dysbiosis element development various cancers, including Thus, better understanding interactions could provide novel alternatives treatment management. In review, we summarize current evidence regarding intricate relationship between microbiome. We discuss arising associations future perspectives field.
Language: Английский
Citations
10
Cancer Nanotechnology, Journal Year: 2025, Volume and Issue: 16(1)
Published: Jan. 17, 2025
Emphasizing the significance of cancer-associated fibroblasts (CAFs), non-malignant yet pivotal players within tumor microenvironment (TME), this review illuminates role inflammatory subtype (iCAF) as catalysts in cancer proliferation, metastasis, and therapeutic resistance. Given their paramount importance, targeting CAFs emerges a robust strategy evolving landscape immunotherapy. Nanomaterials, distinguished by unique features malleability, hold considerable promise biomedicine, especially precision-oriented domain therapy. Their aptitude for modulating immune responses, amplifying drug efficacy through precise delivery, discerningly focusing on cells TME situates nanomaterials formidable tools to transcend boundaries set conventional treatments. This scrutinizes convoluted interplay among CAFs, cells, TME. It further showcases widely utilized management. We underscore potential nanoscale delivery systems directed at underscoring transformative power revolutionizing therapies, enhancing precision, culminating improved patient outcomes.
Language: Английский
Citations
2
APL Bioengineering, Journal Year: 2025, Volume and Issue: 9(1)
Published: March 1, 2025
Cancer-associated fibroblasts (CAFs) play a crucial role in the tumor microenvironment by promoting growth, immune evasion, and metastasis. Recently, drug delivery systems targeting CAFs have emerged as promising long-term effective approach to cancer treatment. Advances nanotechnology, particular, led development of nanomedicine designed specifically target CAFs, offering new possibilities for precise personalized therapies. This article reviews recent progress using nanocarriers that CAFs. Additionally, we explore potential combining multiple therapies, such chemotherapy immunotherapy, with enhance efficacy overcome resistance. Although many preclinical studies show promise, clinical application still faces considerable challenges, especially terms penetration large-scale production. Therefore, this review aims provide fresh perspective on CAF-targeted highlight future research directions applications.
Language: Английский
Citations
1
European Radiology Experimental, Journal Year: 2025, Volume and Issue: 9(1)
Published: Feb. 18, 2025
The objective of this study was to evaluate the therapeutic effectiveness and safety transarterial chemoembolization (TACE) combined with programmed cell death-1 (PD-1) inhibitors lenvatinib in treatment unresectable intrahepatic cholangiocarcinoma (uICC). This multicenter retrospective screened patients uICC who underwent TACE combination PD-1 between January 2019 June 2023. Tislelizumab or camrelizumab (200 mg) intravenously administered every three weeks. daily dose 8 mg for weighing < 60 kg 12 those ≥ kg. In cases disease progression, strategy adjusted based on clinical condition individual patient's preferences. Options included transitioning standard supportive care continuing lenvatinib. primary outcomes were overall survival (OS) progression-free (PFS), while secondary response rate (ORR), control (DCR), incidence adverse events (AEs). A total 59 included. Over a median follow-up period 32.3 months, OS PFS 25.8 months (95% confidence interval [CI]: 17.9-33.7) 9.5 CI: 7.9-11.0), respectively. ORR 55.9%, DCR 96.6%. Grade 3 four AEs observed 15 (25.4%). demonstrated promising potential manageable profile uICC. TACE, inhibitors, represents novel option plus represent manageable. improved compared prior standard-of-care treatments.
Language: Английский
Citations
1
Journal of Controlled Release, Journal Year: 2025, Volume and Issue: 381, P. 113606 - 113606
Published: March 5, 2025
Language: Английский
Citations
1
International Immunopharmacology, Journal Year: 2024, Volume and Issue: 141, P. 113001 - 113001
Published: Aug. 25, 2024
Language: Английский
Citations
6